サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566812

心臓発作診断市場：タイプ別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年

Heart Attack Diagnostics Market By Type (Electrocardiogram, Blood Tests, Angiogram, Computerized Cardiac Tomography, Others), By End User (Hospitals, Diagnostics Centers, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 260 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
心臓発作診断市場：タイプ別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 260 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

心臓発作診断市場

心臓発作診断市場は、2023年に92億米ドルと評価され、2024～2033年にかけてCAGR 8.6%で成長し、2033年には211億米ドルに達すると予測されています。

心臓発作診断は、患者の血圧、体温、脈拍数を診断することからなります。心筋梗塞としても知られる心臓発作を経験したかどうかを判断するために、一連の評価が行われます。一連の診断試験には、心臓の電気的活動を測定する心電図（EKG）、心筋が損傷した場合に血液中に放出されるトロポニンなどの心筋酵素を検出するための血液試験、心臓とその血管を可視化するための冠動脈造影試験や心エコー試験などの画像試験が含まれます。

座りがちなライフスタイルの増加は、心臓発作を含む生活習慣病の急増につながっています。このため、心臓発作診断の需要が急増し、市場の成長が加速しています。さらに、世界の高齢者人口の急激な増加が市場拡大の道を開いています。心電図試験にAIを導入することは、診断時間の短縮につながるため、将来的に主流になる可能性があります。台湾のある病院では、AIと心電図の同化に関する調査を実施し、診断時間を10分短縮しました。AIの絶え間ない改良は、臨床判断支援システムの有効性を高め、医療従事者にこの技術の採用を促しています。

しかし、これらの診断試験は非常に高価であるため、エンドユーザーがその利点を活用することができず、市場開拓を抑制しています。加えて、新しい診断技術の導入には様々な規制上のハードルがあり、市場拡大の課題となっています。米国食品医薬品局、欧州医薬品庁、日本の医薬品医療機器総合機構、インドの中央医薬品標準管理機構など、さまざまな規制機関が新しい診断技術の市場参入について、それぞれの規制ガイドラインの遵守を義務付けています。反対に、革新的な技術が市場に導入されていることは、その有望な将来を示す指標です。例えば、ドイツの医療企業であるシーメンス・ヘルティニアーズは、30分以内に心臓発作を検出できるとするハンドヘルド機器を発表しました。このような機器の発売により、治療が迅速に行われ、患者の回復の可能性が高まることが期待されます。

セグメント別レビュー

心臓発作診断市場は、タイプ、エンドユーザー、地域に区分されます。タイプ別では、市場は心電図、血液試験、血管造影、コンピュータ心臓断層撮影、その他に分けられます。エンドユーザー別では、病院、診断センター、その他に分類されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されています。

本レポートのカスタマイズが可能です。

  • 顧客の関心に応じた企業プロファイルの追加
  • 企業プロファイルの拡大リスト
  • 過去の市場データ

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 心臓発作診断市場：タイプ別

  • 市場概要
  • 心電図
  • 血液試験
  • 血管造影
  • コンピューター心臓断層撮影
  • その他

第5章 心臓発作診断市場：エンドユーザー別

  • 市場概要
  • 病院
  • 診断センター
  • その他

第6章 心臓発作診断市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国の心臓発作診断市場
    • カナダの心臓発作診断市場
    • メキシコの心臓発作診断市場
  • 欧州
    • 主要市場動向と機会
    • フランスの心臓発作診断市場
    • ドイツの心臓発作診断市場
    • イタリアの心臓発作診断市場
    • スペインの心臓発作診断市場
    • 英国の心臓発作診断市場
    • その他の欧州の心臓発作診断市場
  • アジア太平洋
    • 主要市場動向と機会
    • 中国の心臓発作診断市場
    • 日本の心臓発作診断市場
    • インドの心臓発作診断市場
    • 韓国の心臓発作診断市場
    • オーストラリアの心臓発作診断市場
    • その他のアジア太平洋の心臓発作診断市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルの心臓発作診断市場
    • 南アフリカの心臓発作診断市場
    • サウジアラビアの心臓発作診断市場
    • その他のラテンアメリカ・中東・アフリカの心臓発作診断市場

第7章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第8章 企業プロファイル

  • Bionet Co., Ltd
  • TOSHIBA CORPORATION
  • Bio-Rad Laboratories Inc
  • Life Sign LLC
  • Schiller AG
  • Beckman Coulter, Inc.
  • GE Healthcare
  • Hitachi Medical Systems
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
目次
Product Code: A12689

Heart Attack Diagnostics Market

The heart attack diagnostics market was valued at $9.2 billion in 2023 and is projected to reach $21.1 billion by 2033, growing at a CAGR of 8.6% from 2024 to 2033.

Heart attack diagnostic comprises of diagnosing the blood pressure, temperature, and pulse rate of a patient. A series of evaluations are conducted to determine if an individual has experienced a heart attack, also known as myocardial infarction. The series of diagnostic tests includes an electrocardiogram (EKG) which measures the electrical activity of heart, blood tests to detect cardiac enzymes such as troponin which are released into the bloodstream in case of heart muscle damage, and imaging tests such as coronary angiography or echocardiography for the visualization of heart & its blood vessels.

Increase in sedentary lifestyles has led to surge in occurrence of lifestyle diseases, including heart attack. This has led to surge in demand for heart attack diagnostics, hence augmenting the growth of the market. Furthermore, exponential growth in the geriatric population globally is opening avenues for the expansion of the market. The assimilation of AI in the EKG testing is poised to become mainstream in the future as it reduces the diagnosis time. A hospital in Taiwan conducted research regarding the assimilation of AI and EKG, which reduced the diagnosis period by 10 minutes. Constant improvements in AI are enhancing the efficacy of clinical decision support system, encouraging medical practitioners to adopt the technology.

However, these diagnostics tests are extremely expensive and prevent several end users from leveraging their benefits, hence restraining the market development. In addition, the introduction of new diagnostic technologies is subject to various regulatory hurdles, hence presenting challenges for the expansion of the market. Different regulatory bodies such as the U.S. Food and Drug Administration, European Medicines Agency, the Pharmaceuticals and Medical Devices Agency in Japan, and Central Drugs Standard Control Organization in India have mandated the adherence to their respective regulatory guidelines for the entry of new diagnostic technologies into the market. Contrarily, innovative techniques being introduced into the market are an indicator of its promising future. For instance, Siemens Healthineers, a German healthcare company, has introduced a handheld device which claims to detect heart attack in less than 30 minutes. The launch of such devices is expected to quicken treatment delivery and increase the chances of recovery for patients in the future.

Segment Review

The heart attack diagnostics market is segmented into type, end user, and region. On the basis of type, the market is divided into electrocardiogram, blood tests, angiogram, computerized cardiac tomography, and others. By end user, it is classified into hospitals, diagnostics centers, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Competition Analysis

The major players operating in the global heart attack diagnostics market include Bionet Co., Ltd, TOSHIBA CORPORATION, Bio-Rad Laboratories Inc, Life Sign LLC, Schiller AG, Beckman Coulter,Inc., GE Healthcare, Hitachi Medical Systems, F. Hoffmann-La Roche Ltd., and Abbott Laboratories. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Type

  • Electrocardiogram
  • Blood Tests
  • Angiogram
  • Computerized Cardiac Tomography
  • Others

By End User

  • Hospitals
  • Diagnostics Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Bionet Co., Ltd
    • TOSHIBA CORPORATION
    • Bio-Rad Laboratories Inc
    • Life Sign LLC
    • Schiller AG
    • Beckman Coulter,Inc.
    • GE Healthcare
    • Hitachi Medical Systems
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.5. Market Dynamics
    • 3.5.1. Drivers
    • 3.5.2. Restraints
    • 3.5.3. Opportunities

CHAPTER 4: HEART ATTACK DIAGNOSTICS MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Electrocardiogram
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Blood Tests
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Angiogram
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Computerized Cardiac Tomography
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6. Others
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country

CHAPTER 5: HEART ATTACK DIAGNOSTICS MARKET, BY END USER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By End User
  • 5.2. Hospitals
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Diagnostics Centers
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Others
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: HEART ATTACK DIAGNOSTICS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Type
    • 6.2.3. Market Size and Forecast, By End User
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Heart Attack Diagnostics Market
      • 6.2.5.1. Market Size and Forecast, By Type
      • 6.2.5.2. Market Size and Forecast, By End User
    • 6.2.6. Canada Heart Attack Diagnostics Market
      • 6.2.6.1. Market Size and Forecast, By Type
      • 6.2.6.2. Market Size and Forecast, By End User
    • 6.2.7. Mexico Heart Attack Diagnostics Market
      • 6.2.7.1. Market Size and Forecast, By Type
      • 6.2.7.2. Market Size and Forecast, By End User
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Type
    • 6.3.3. Market Size and Forecast, By End User
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. France Heart Attack Diagnostics Market
      • 6.3.5.1. Market Size and Forecast, By Type
      • 6.3.5.2. Market Size and Forecast, By End User
    • 6.3.6. Germany Heart Attack Diagnostics Market
      • 6.3.6.1. Market Size and Forecast, By Type
      • 6.3.6.2. Market Size and Forecast, By End User
    • 6.3.7. Italy Heart Attack Diagnostics Market
      • 6.3.7.1. Market Size and Forecast, By Type
      • 6.3.7.2. Market Size and Forecast, By End User
    • 6.3.8. Spain Heart Attack Diagnostics Market
      • 6.3.8.1. Market Size and Forecast, By Type
      • 6.3.8.2. Market Size and Forecast, By End User
    • 6.3.9. UK Heart Attack Diagnostics Market
      • 6.3.9.1. Market Size and Forecast, By Type
      • 6.3.9.2. Market Size and Forecast, By End User
    • 6.3.10. Rest of Europe Heart Attack Diagnostics Market
      • 6.3.10.1. Market Size and Forecast, By Type
      • 6.3.10.2. Market Size and Forecast, By End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Type
    • 6.4.3. Market Size and Forecast, By End User
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. China Heart Attack Diagnostics Market
      • 6.4.5.1. Market Size and Forecast, By Type
      • 6.4.5.2. Market Size and Forecast, By End User
    • 6.4.6. Japan Heart Attack Diagnostics Market
      • 6.4.6.1. Market Size and Forecast, By Type
      • 6.4.6.2. Market Size and Forecast, By End User
    • 6.4.7. India Heart Attack Diagnostics Market
      • 6.4.7.1. Market Size and Forecast, By Type
      • 6.4.7.2. Market Size and Forecast, By End User
    • 6.4.8. South Korea Heart Attack Diagnostics Market
      • 6.4.8.1. Market Size and Forecast, By Type
      • 6.4.8.2. Market Size and Forecast, By End User
    • 6.4.9. Australia Heart Attack Diagnostics Market
      • 6.4.9.1. Market Size and Forecast, By Type
      • 6.4.9.2. Market Size and Forecast, By End User
    • 6.4.10. Rest of Asia-Pacific Heart Attack Diagnostics Market
      • 6.4.10.1. Market Size and Forecast, By Type
      • 6.4.10.2. Market Size and Forecast, By End User
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Type
    • 6.5.3. Market Size and Forecast, By End User
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Heart Attack Diagnostics Market
      • 6.5.5.1. Market Size and Forecast, By Type
      • 6.5.5.2. Market Size and Forecast, By End User
    • 6.5.6. South Africa Heart Attack Diagnostics Market
      • 6.5.6.1. Market Size and Forecast, By Type
      • 6.5.6.2. Market Size and Forecast, By End User
    • 6.5.7. Saudi Arabia Heart Attack Diagnostics Market
      • 6.5.7.1. Market Size and Forecast, By Type
      • 6.5.7.2. Market Size and Forecast, By End User
    • 6.5.8. Rest of LAMEA Heart Attack Diagnostics Market
      • 6.5.8.1. Market Size and Forecast, By Type
      • 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Bionet Co., Ltd
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. TOSHIBA CORPORATION
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Bio-Rad Laboratories Inc
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Life Sign LLC
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Schiller AG
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Beckman Coulter, Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. GE Healthcare
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Hitachi Medical Systems
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. F. Hoffmann-La Roche Ltd.
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Abbott Laboratories
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments